Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

4-PrO-DMT

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
4-PrO-DMT
Clinical data
Other names4-Propionyloxy-N,N-dimethyltryptamine; 4-Propionyloxy-DMT; 4-Propanoyloxy-DMT;O-Propionylpsilocin
Routes of
administration
Oral
Drug classNon-selectiveserotonin receptor agonist;Serotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen
Identifiers
  • [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] propanoate
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC15H20N2O2
Molar mass260.337 g·mol−1
3D model (JSmol)
  • CCC(=O)OC1=CC=CC2=C1C(=CN2)CCN(C)C
  • InChI=1S/C15H20N2O2/c1-4-14(18)19-13-7-5-6-12-15(13)11(10-16-12)8-9-17(2)3/h5-7,10,16H,4,8-9H2,1-3H3
  • Key:KUOGXPDQORRHED-UHFFFAOYSA-N

4-PrO-DMT, also known as4-propionyloxy-N,N-dimethyltryptamine or asO-propionylpsilocin, is asyntheticpsychedelic drug of thetryptamine family withpsychedelic that is believed to act as aprodrug ofpsilocin (4-HO-DMT).[1] It has been sold online as adesigner drug since May 2019. It was first identified as a newpsychoactive substance in Sweden, in July 2019.[2] A number of related derivatives have been synthesized asprodrugs ofpsilocin for medical applications.[3]

Use and effects

[edit]
See also:Psilocin § Uses,Psilocin § Effects,Psilocybin § Uses, andPsilocybin § Effects
4-PrO-DMT Crystals
4-PrO-DMT crystals.

4-PrO-DMT is reported to beorally active and while effects have been studied in mice, its effects and longevity on humans have not been formally studied. The effects of 4-PrO-DMT are similar to those ofpsilocin (4-HO-DMT), as it acts as aprodrug of this compound.[1][4] This is analogous to the case of4-AcO-DMT andpsilocybin (4-PO-DMT).

Toxicity

[edit]

Very little data about thetoxicity orpharmacology of 4-PrO-DMT is known. Its chemical structure andpharmacological activity are similar topsilacetin, a compound which isn't associated with compulsive use or physical dependence. However, due to lack of research and data, it cannot be definitively concluded that its pharmacological actions in the human body do not differ from those ofpsilacetin. To date, there have been no reported deaths from 4-PrO-DMT.[1]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
Psilocin at molecular targets
TargetAffinity (Ki, nM)
5-HT1A49–567 (Ki)
130–>3,160 (EC50Tooltip half-maximal effective concentration)
0.7%–96% (EmaxTooltip maximal efficacy)
5-HT1B31–305
5-HT1D19–36
5-HT1E44–52
5-HT1FND
5-HT2A6.0–340 (Ki)
2.4–3,836 (EC50)
16–98% (
Emax)
5-HT2B4.6–410 (Ki)
2.4–>20,000 (EC50)
1.4–84% (
Emax)
5-HT2C10–141 (Ki)
9.1–30 (EC50)
86–95% (
Emax)
5-HT3>10,000
5-HT4ND
5-HT5A70–84
5-HT657–72
5-HT73.5–72
α1Aα1B>10,000
α2A1,379–2,044
α2B1,271–1,894
α2C4,404
β1β2>10,000
D120–>14,000
D23,700–>10,000
D3101–8,900
D4>10,000
D5>10,000
H11,600–>10,000
H2H4>10,000
M1M5>10,000
σ1>10,000
σ2>10,000
I2792
TAAR11,400 (Ki) (rat)
17,000 (Ki) (mouse)
920–2,700 (EC50) (rodent)
>30,000 (
EC50) (human)
SERTTooltip Serotonin transporter3,650–>10,000 (Ki)
662–3,900 (IC50Tooltip half-maximal inhibitory concentration)
561 (EC50)
54% (
Emax)
NETTooltip Norepinephrine transporter13,000 (Ki)
14,000 (IC50)
>10,000 (
EC50)
DATTooltip Dopamine transporter6,000–>30,000 (Ki)
>100,000 (IC50)
>10,000 (
EC50)
Notes: The smaller the value, the more avidly psilocin interacts with the site.Sources:[5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]

4-PrO-DMT is theorized to be aserotonergicpsychedelic, and ispartial agonist of the5-HT1D,5-HT1B and5-HT1Aserotonin receptors.[1][24] It produces thehead-twitch response in mice.[1]

Chemistry

[edit]

Analogues

[edit]

Analogues of 4-PrO-DMT include4-HO-DMT (psilocin),4-AcO-DMT (psilacetin),4-PrO-DiPT,4-GO-DMT,luvesilocin (4-GO-DiPT), andpsilocybin (4-PO-DMT), among others.

See also

[edit]

References

[edit]
  1. ^abcdeGlatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, Baumann MH (April 2023)."Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice".ACS Pharmacology & Translational Science.6 (4):567–577.doi:10.1021/acsptsci.2c00222.PMC 10111620.PMID 37082754.
  2. ^European Monitoring Center for Drugs and Drug Addiction (December 2020).New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System(PDF). Luxembourg: Publications Office of the European Union.doi:10.2810/921262.ISBN 9789294975584.Archived(PDF) from the original on 2022-10-08. Retrieved2021-06-17.
  3. ^Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, et al. (November 2023)."Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders".Journal of Medicinal Chemistry.67 (2):1024–1043.doi:10.1021/acs.jmedchem.3c01225.PMC 10823477.PMID 37983270.
  4. ^"Foundational Science for the Psilocybin Analog 4-PrO-DMT in Mice".CaaMTech. 28 March 2023.Archived from the original on 2024-03-03.
  5. ^Liu T."BindingDB BDBM50081701 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol::4-hydroxy-N,N-dimethyltryptamine::CHEMBL65547::N,N-dimethyl-4-hydroxytryptamine::Psilocin::US11427604, Compound (I-45)::US11453689, Compound Psilocin::US11591353, Compound I-45::US11597738, Example 3::US11642336, Compound Psilocin::US20240051978, Compound Psilocin".BindingDB. Retrieved5 September 2024.
  6. ^Liu T."BindingDB BDBM50171269 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate::4-phosphoryloxy-N,N-dimethyltryptamine::CHEMBL194378::Indocybin::O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine::Psilocybine::US11597738, Example 4::psilocin phosphate ester::psilocybin".BindingDB. Retrieved5 September 2024.
  7. ^"PDSP Database".UNC (in Zulu). Retrieved2024-09-05.
  8. ^"PDSP Database".UNC (in Zulu). Retrieved2024-09-05.
  9. ^Holze F, Singh N, Liechti ME, D'Souza DC (May 2024)."Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile".Biol Psychiatry Cogn Neurosci Neuroimaging.9 (5):472–489.doi:10.1016/j.bpsc.2024.01.007.PMID 38301886.
  10. ^Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M (August 2023)."Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy"(PDF).CNS Spectr.28 (4):416–426.doi:10.1017/S1092852922000888.PMID 35811423.
  11. ^Tylš F, Páleníček T, Horáček J (March 2014)."Psilocybin - summary of knowledge and new perspectives".Eur Neuropsychopharmacol.24 (3):342–356.doi:10.1016/j.euroneuro.2013.12.006.PMID 24444771.
  12. ^Wojtas A, Gołembiowska K (December 2023)."Molecular and Medical Aspects of Psychedelics".Int J Mol Sci.25 (1): 241.doi:10.3390/ijms25010241.PMC 10778977.PMID 38203411.
  13. ^Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016)."Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens"(PDF).Eur Neuropsychopharmacol.26 (8):1327–1337.doi:10.1016/j.euroneuro.2016.05.001.PMID 27216487.
  14. ^Ray TS (February 2010)."Psychedelics and the human receptorome".PLOS ONE.5 (2) e9019.Bibcode:2010PLoSO...5.9019R.doi:10.1371/journal.pone.0009019.PMC 2814854.PMID 20126400.
  15. ^Plazas E, Faraone N (February 2023)."Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents".Biomedicines.11 (2): 461.doi:10.3390/biomedicines11020461.PMC 9953455.PMID 36830997.
  16. ^US 11440879, Andrew Carry Kruegel, "Methods of treating mood disorders", published 10 February 2022, assigned to Gilgamesh Pharmaceuticals, Inc. 
  17. ^Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012)."Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters".The Journal of Pharmacology and Experimental Therapeutics.341 (1):251–262.doi:10.1124/jpet.111.188946.PMC 3364510.PMID 22271821.
  18. ^Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014)."Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes".Psychopharmacology (Berl).231 (21):4135–4144.doi:10.1007/s00213-014-3557-7.PMC 4194234.PMID 24800892.
  19. ^Marek GJ, Makai-Bölöni S, Umbricht D, Christian EP, Winters J, Dvorak D, Raines S, Hughes ZA, Austin EW, Klein AK, Leong W, Krol FJ, Graaf AJ, Juachon MJ, Otto ME, Borghans LG, Jacobs G, Kruegel AC, Sporn J (October 2025). "A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer".J Psychopharmacol 2698811251378512.doi:10.1177/02698811251378512.PMID 41099491.
  20. ^Wsół A (December 2023)."Cardiovascular safety of psychedelic medicine: current status and future directions".Pharmacol Rep.75 (6):1362–1380.doi:10.1007/s43440-023-00539-4.PMC 10661823.PMID 37874530.
  21. ^Chen X, Li J, Yu L, Maule F, Chang L, Gallant JA, Press DJ, Raithatha SA, Hagel JM, Facchini PJ (October 2023)."A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines".J Biol Chem.299 (10) 105231.doi:10.1016/j.jbc.2023.105231.PMC 10570959.PMID 37690691.
  22. ^Chen X, Li J, Yu L, Dhananjaya D, Maule F, Cook S, Chang L, Gallant J, Press D, Bains JS, Raithatha S, Hagel J, Facchini P (10 March 2023),Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery(PDF),doi:10.21203/rs.3.rs-2667175/v1, retrieved18 March 2025
  23. ^Gainetdinov RR, Hoener MC, Berry MD (July 2018)."Trace Amines and Their Receptors".Pharmacol Rev.70 (3):549–620.doi:10.1124/pr.117.015305.PMID 29941461.
  24. ^Greene, Shaun L. (2022-01-01), Dargan, Paul; Wood, David (eds.),"Chapter18 - Tryptamines",Novel Psychoactive Substances (Second Edition), Boston: Academic Press, pp. 495–532,doi:10.1016/b978-0-12-818788-3.00014-0,ISBN 978-0-12-818788-3, retrieved2024-08-29

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
TAAR1Tooltip Trace amine-associated receptor 1
Agonists
Endogenous
Exogenous
Antagonists
Inverse agonists
TAAR5Tooltip Trace amine-associated receptor 5
Agonists
Inverse agonists
Notes: (1) TAAR1 activity of ligands varies significantly between species. Some agents that are TAAR1 ligands in some species are not in other species. This navbox includes all TAAR1 ligands regardless of species. (2) See the individual pages for references, as well as theList of trace amines,TAAR, andTAAR1 pages.
See also:Receptor/signaling modulators
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=4-PrO-DMT&oldid=1322748337"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp